These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
California
|
|
94-2424084
|
|
(State or other
jurisdiction of
|
|
(I.R.S. Employer
Identification No.)
|
|
incorporation or
organization)
|
|
|
|
|
|
|
|
400 Kato
Terrace
|
|
|
|
Fremont,
CA
|
|
94539
|
|
(Address of
principal
|
|
(Zip
Code)
|
|
executive
offices)
|
|
|
|
PART
I. FINANCIAL INFORMATION
|
|
|
|
|
|
ITEM
1. Financial Statements (Unaudited)
|
|
|
|
|
|
Condensed Consolidated Balance Sheets at February 28, 2017 and May
2016
|
4
|
|
|
|
|
Condensed Consolidated Statements of
Operations for the Three and Nine Months Ended
February
28, 2017 and February 29, 2016
|
5
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Loss for the
Three and Nine Months Ended
February
28, 2017 and February 29, 2016
|
6
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the Nine Months
Ended
February
28, 2017 and February 29, 2016
|
7
|
|
|
|
|
Notes
to Condensed Consolidated Financial Statements
|
8
|
|
|
|
|
ITEM
2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
|
18
|
|
|
|
|
ITEM
3. Quantitative and Qualitative Disclosures About Market
Risks
|
24
|
|
|
|
|
ITEM
4. Controls and Procedures
|
24
|
|
|
|
|
|
|
|
PART
II. OTHER INFORMATION
|
|
|
|
|
|
ITEM
1. Legal Proceedings
|
26
|
|
|
|
|
ITEM
1A. Risk Factors
|
26
|
|
|
|
|
ITEM
2. Unregistered Sales of Equity Securities and Use of
Proceeds
|
33
|
|
|
|
|
ITEM
3. Defaults Upon Senior Securities
|
33
|
|
|
|
|
ITEM
4. Mine Safety Disclosures
|
33
|
|
|
|
|
ITEM
5. Other Information
|
33
|
|
|
|
|
ITEM
6. Exhibits
|
33
|
|
|
|
|
SIGNATURES
|
34
|
|
|
|
|
35
|
|
|
February 28,
|
May 31,
|
|
|
2017
|
2016
|
|
|
(1
)
|
|
|
ASSETS
|
|
|
|
Current
assets:
|
|
|
|
Cash
and cash equivalents
|
$
2,039
|
$
939
|
|
Accounts
receivable, net
|
1,596
|
522
|
|
Inventories
|
7,207
|
7,033
|
|
Prepaid
expenses and other current assets
|
354
|
254
|
|
|
|
|
|
Total
current assets
|
11,196
|
8,748
|
|
|
|
|
|
Property
and equipment, net
|
861
|
1,204
|
|
Other
assets
|
96
|
94
|
|
|
|
|
|
Total
assets
|
$
12,153
|
$
10,046
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS' EQUITY (DEFICIT)
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$
1,821
|
$
1,413
|
|
Accrued
expenses
|
1,897
|
1,553
|
|
Customer
deposits and deferred revenue, short-term
|
1,012
|
1,714
|
|
|
|
|
|
Total
current liabilities
|
4,730
|
4,680
|
|
|
|
|
|
Long-term
debt, net of debt issuance costs
|
6,095
|
5,962
|
|
Deferred
revenue, long-term
|
32
|
127
|
|
|
|
|
|
Total
liabilities
|
10,857
|
10,769
|
|
|
|
|
|
Aehr
Test Systems shareholders' equity (deficit):
|
|
|
|
Common
stock, $0.01 par value:
|
|
|
|
Authorized: 75,000 shares;
Issued
and outstanding: 16,754 shares and
13,216
shares at February 28, 2017 and
May 31, 2016,
respectively
|
168
|
132
|
|
Additional
paid-in capital
|
64,939
|
58,052
|
|
Accumulated
other comprehensive income
|
2,190
|
2,237
|
|
Accumulated
deficit
|
(65,982
)
|
(61,124
)
|
|
|
|
|
|
Total
Aehr Test Systems shareholders' equity (deficit)
|
1,315
|
(703
)
|
|
Noncontrolling
interest
|
(19
)
|
(20
)
|
|
|
|
|
|
Total
shareholders' equity (deficit)
|
1,296
|
(723
)
|
|
|
|
|
|
Total
liabilities and shareholders' equity (deficit)
|
$
12,153
|
$
10,046
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
Net
sales
|
$
2,681
|
$
1,677
|
$
12,215
|
$
12,930
|
|
Cost
of sales
|
2,178
|
1,508
|
8,043
|
7,687
|
|
Gross
profit
|
503
|
169
|
4,172
|
5,243
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
Selling,
general and administrative
|
1,724
|
1,695
|
5,147
|
5,253
|
|
Research
and development
|
1,248
|
1,293
|
3,348
|
3,278
|
|
Total
operating expenses
|
2,972
|
2,988
|
8,495
|
8,531
|
|
|
|
|
|
|
|
Loss
from operations
|
(2,469
)
|
(2,819
)
|
(4,323
)
|
(3,288
)
|
|
|
|
|
|
|
|
Interest
expense
|
(178
)
|
(165
)
|
(537
)
|
(437
)
|
|
Other
(expense) income, net
|
(2
)
|
(24
)
|
38
|
7
|
|
|
|
|
|
|
|
Loss before income tax
(expense) benefit
|
(2,649
)
|
(3,008
)
|
(4,822
)
|
(3,718
)
|
|
Income
tax (expense) benefit
|
(2
)
|
33
|
(36
)
|
(11
)
|
|
Net
loss
|
(2,651
)
|
(2,975
)
|
(4,858
)
|
(3,729
)
|
|
|
|
|
|
|
|
Less:
Net income attributable to
the noncontrolling
interest
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
Net loss
attributable to
Aehr Test Systems
common shareholders
|
$
(2,651
)
|
$
(2,975
)
|
$
(4,858
)
|
$
(3,729
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per share
|
|
|
|
|
|
Basic
and Diluted
|
$
(0.16
)
|
$
(0.23
)
|
$
(0.32
)
|
$
(0.29
)
|
|
|
|
|
|
|
|
Shares
used in per share calculations:
|
|
|
|
|
|
Basic
and Diluted
|
16,672
|
13,164
|
15,411
|
13,058
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
|
|
|
|
|
|
Net
loss
|
$
(2,651
)
|
$
(2,975
)
|
$
(4,858
)
|
$
(3,729
)
|
|
|
|
|
|
|
|
Other comprehensive
income (loss), net of tax:
|
|
|
|
|
|
Net
change in cumulative translation
adjustments
|
2
|
23
|
(46
)
|
(19
)
|
|
|
|
|
|
|
|
Total comprehensive
loss
|
(2,649
)
|
(2,952
)
|
(4,904
)
|
(3,748
)
|
|
Less: Comprehensive
(loss) income attributable
to the
noncontrolling interest
|
--
|
(1
)
|
1
|
(1
)
|
|
|
|
|
|
|
|
Comprehensive
loss
, attributable to
Aehr
Test Systems common shareholders
|
$
(2,649
)
|
$
(2,951
)
|
$
(4,905
)
|
$
(3,747
)
|
|
|
Nine Months
Ended
|
|
|
|
February 28,
|
February 29,
|
|
|
2017
|
2016
|
|
Cash
flows from operating activities:
|
|
|
|
Net
loss
|
$
(4,858
)
|
$
(3,729
)
|
|
Adjustments to reconcile net loss to
net cash used in
operating activities:
|
|
|
|
Stock-based
compensation expense
|
791
|
786
|
|
Provision
for doubtful accounts
|
16
|
8
|
|
Amortization
of debt issuance costs
|
133
|
126
|
|
Depreciation
and amortization
|
195
|
123
|
|
Changes
in operating assets and liabilities:
|
|
|
|
Accounts
receivable
|
(1,119
)
|
(592
)
|
|
Inventories
|
197
|
(275
)
|
|
Prepaid
expenses and other assets
|
(100
)
|
(34
)
|
|
Accounts
payable
|
726
|
1,068
|
|
Accrued
expenses
|
325
|
434
|
|
Customer
deposits and deferred revenue
|
(797
)
|
(2,597
)
|
|
Income
taxes payable
|
23
|
(25
)
|
|
Net
cash used in operating activities
|
(4,468
)
|
(4,707
)
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
Purchases
of property and equipment
|
(219
)
|
(890
)
|
|
Net
cash used in investing activities
|
(219
)
|
(890
)
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
Line
of credit borrowings (repayments), net
|
--
|
2,000
|
|
Proceeds from issuance of common stock
under private
placement, net of issuance costs
|
5,299
|
--
|
|
Proceeds
from issuance of common stock
under employee plans, net of
taxes paid related
to share settlement of equity
awards
|
510
|
460
|
|
Net
cash provided by financing activities
|
5,809
|
2,460
|
|
|
|
|
|
Effect
of exchange rates on cash and cash equivalents
|
(22
)
|
82
|
|
|
|
|
|
Net increase (decrease) in cash and
cash
equivalents
|
1,100
|
(3,055
)
|
|
|
|
|
|
Cash
and cash equivalents, beginning of period
|
939
|
5,527
|
|
|
|
|
|
Cash
and cash equivalents, end of period
|
$
2,039
|
$
2,472
|
|
Supplemental
disclosure of non-cash flow information:
|
|
|
|
Net
change in capitalized share-based compensation
|
$
--
|
$
(20
)
|
|
Fair
value of common stock issued to settle accounts
payable
|
$
323
|
$
--
|
|
Transfer
of property and equipment to inventories
|
$
372
|
$
--
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
Stock-based
compensation in the form of employee stock options, RSUs and ESPP
purchase rights, included in:
|
|
|
|
|
|
Cost
of sales
|
$
22
|
$
20
|
$
69
|
$
62
|
|
Selling,
general and administrative
|
187
|
145
|
575
|
569
|
|
Research
and development
|
48
|
48
|
147
|
155
|
|
Total
stock-based compensation
|
$
257
|
$
213
|
$
791
|
$
786
|
|
|
Three Months Ended
|
Nine Months Ended
|
|
|
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2016
|
2017
|
2016
|
|
|
|
|
|
|
Expected
term (in years)
|
4
|
4
|
4
|
|
Volatility
|
0.80
|
0.81
|
0.86
|
|
Risk-free
interest rates
|
1.23
%
|
1.02
%
|
1.21
%
|
|
Weighted
average grant date fair value
|
$
0.80
|
$
1.09
|
$
1.31
|
|
|
Available
|
|
|
Shares
|
|
Balance,
May 31, 2016
|
1,847
|
|
|
|
|
Options
granted
|
(318
)
|
|
RSUs
granted
|
(138
)
|
|
Shares
cancelled
|
46
|
|
|
|
|
Balance,
August 31, 2016
|
1,437
|
|
|
|
|
Additional
shares reserved
|
2,238
|
|
Options
granted
|
(50
)
|
|
Shares
cancelled
|
1
|
|
2006
Plan available shares expired
|
(1,438
)
|
|
|
|
|
Balance,
November 30, 2016
|
2,188
|
|
|
|
|
RSUs
granted
|
(19
)
|
|
|
|
|
Balance,
February 28, 2017
|
2,169
|
|
|
Outstanding Options
|
||
|
|
|
Weighted
|
|
|
|
Number
|
Average
|
Aggregate
|
|
|
of
|
Exercise
|
Intrinsic
|
|
|
Shares
|
Price
|
Value
|
|
Balances,
May 31, 2016
|
3,201
|
$
1.66
|
$
189
|
|
|
|
|
|
|
Options
granted
|
318
|
$
1.68
|
|
|
Options
cancelled
|
(46
)
|
$
1.40
|
|
|
Options
exercised
|
(91
)
|
$
1.32
|
|
|
|
|
|
|
|
Balances,
August 31, 2016
|
3,382
|
$
1.67
|
$
2,694
|
|
|
|
|
|
|
Options
granted
|
50
|
$
2.81
|
|
|
Options
cancelled
|
(1
)
|
$
2.08
|
|
|
Options
exercised
|
(202
)
|
$
1.22
|
|
|
|
|
|
|
|
Balances,
November 30, 2016
|
3,229
|
$
1.72
|
$
4,099
|
|
|
|
|
|
|
Options
exercised
|
(72
)
|
$
1.60
|
|
|
|
|
|
|
|
Balances,
February 28, 2017
|
3,157
|
$
1.72
|
$
11,101
|
|
|
|
|
|
|
Options fully vested and expected to
vest at February 28,
2017
|
3,113
|
$
1.72
|
$
10,961
|
|
|
|
|
|
|
|
Options
Outstanding
at February 28,
2017
|
Options
Exercisable
at February 28,
2017
|
|||||
|
Range of
Exercise
Prices
|
Number
Outstanding
Shares
|
Weighted
Average
Remaining Contractual Life (Years)
|
Weighted Average
Exercise Price
|
Number
Exercisable Shares
|
Weighted Average
Remaining Contractual Life (Years)
|
Weighted Average Exercise Price |
Aggregate
Intrinsic
Value
|
|
$
0.59-$0.97
|
514
|
2.03
|
$
0.66
|
514
|
2.03
|
$
0.66
|
|
|
$
1.09-$1.40
|
847
|
2.66
|
$
1.28
|
796
|
2.60
|
$
1.28
|
|
|
$
1.68-$2.06
|
546
|
5.38
|
$
1.77
|
264
|
4.40
|
$
1.86
|
|
|
$
2.10-$2.81
|
1,250
|
4.78
|
$
2.44
|
792
|
4.68
|
$
2.45
|
|
|
$
0.59-$2.81
|
3,157
|
3.87
|
$
1.72
|
2,366
|
3.37
|
$
1.60
|
$
8,608
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
|
|
|
|
|
|
Numerator:
Net loss
|
$
(2,651
)
|
$
(2,975
)
|
$
(4,858
)
|
$
(3,729
)
|
|
|
|
|
|
|
|
Denominator for basic net loss
per share:
|
|
|
|
|
|
Weighted-average
shares outstanding
|
16,672
|
13,164
|
15,411
|
13,058
|
|
|
|
|
|
|
|
Shares used in basic net loss
per share
calculation
|
16,672
|
13,164
|
15,411
|
13,058
|
|
Effect
of dilutive securities
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
Denominator for diluted net loss
per share
|
16,672
|
13,164
|
15,411
|
13,058
|
|
|
|
|
|
|
|
Basic
net loss per share
|
$
(0.16
)
|
$
(0.23
)
|
$
(0.32
)
|
$
(0.29
)
|
|
Diluted
net loss per share
|
$
(0.16
)
|
$
(0.23
)
|
$
(0.32
)
|
$
(0.29
)
|
|
|
Balance as of
|
|
|
|
|
|
February 28, 2017
|
Level 1
|
Level 2
|
Level 3
|
|
Money
market funds
|
$
804
|
$
804
|
$
--
|
$
--
|
|
Certificate
of deposit
|
50
|
--
|
50
|
--
|
|
Assets
|
$
854
|
$
804
|
$
50
|
$
--
|
|
|
Balance as of
|
|
|
|
|
|
May 31, 2016
|
Level 1
|
Level 2
|
Level 3
|
|
Money
market funds
|
$
1
|
$
1
|
$
--
|
$
--
|
|
Certificate
of deposit
|
50
|
--
|
50
|
--
|
|
Assets
|
$
51
|
$
1
|
$
50
|
$
--
|
|
|
February
28
,
|
May 31,
|
|
|
2017
|
2016
|
|
Raw
materials and sub-assemblies
|
$
3,330
|
$
2,839
|
|
Work
in process
|
3,636
|
4,151
|
|
Finished
goods
|
241
|
43
|
|
|
$
7,207
|
$
7,033
|
|
|
United
|
|
|
|
|
|
States
|
Asia
|
Europe
|
Total
|
|
Three
months ended February 28, 2017:
|
|
|
|
|
|
Net
sales
|
$
546
|
$
2,017
|
$
118
|
$
2,681
|
|
Property
and equipment, net
|
808
|
39
|
14
|
861
|
|
|
|
|
|
|
|
Nine months ended
February 28,
2017
:
|
|
|
|
|
|
Net
sales
|
$
5,419
|
$
6,183
|
$
613
|
$
12,215
|
|
Property
and equipment, net
|
808
|
39
|
14
|
861
|
|
|
|
|
|
|
|
Three months ended
February 29,
2016
:
|
|
|
|
|
|
Net
sales
|
$
1,235
|
$
380
|
$
62
|
$
1,677
|
|
Property
and equipment, net
|
1,200
|
38
|
13
|
1,251
|
|
|
|
|
|
|
|
Nine months ended
February 29,
2016
:
|
|
|
|
|
|
Net
sales
|
$
2,460
|
$
9,529
|
$
941
|
$
12,930
|
|
Property
and equipment, net
|
1,200
|
38
|
13
|
1,251
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
|
|
|
|
|
|
Balance
at the beginning of the period
|
$
72
|
$
305
|
$
155
|
$
137
|
|
|
|
|
|
|
|
Accruals for warranties issued
during the
period
|
37
|
2
|
48
|
239
|
|
Accruals
and adjustments (change in estimates)
related to
pre-existing warranties during
the period
|
--
|
--
|
(54
)
|
--
|
|
Settlement made during the period
(in cash or in
kind)
|
(23
)
|
(154
)
|
(63
)
|
(223
)
|
|
|
|
|
|
|
|
Balance
at the end of the period
|
$
86
|
$
153
|
$
86
|
$
153
|
|
|
February 28,
|
May 31,
|
|
|
2017
|
2016
|
|
Customer
deposits
|
$
689
|
$
540
|
|
Deferred
revenue
|
323
|
1,174
|
|
|
$
1,012
|
$
1,714
|
|
|
February 28,
|
May 31,
|
|
|
2017
|
2016
|
|
Principal
|
$
6,110
|
$
6,110
|
|
Unamortized
debt issuance costs
|
(15
)
|
(148
)
|
|
|
$
6,095
|
$
5,962
|
|
|
Three Months Ended
|
Nine Months Ended
|
||
|
|
Feb. 28,
|
Feb. 29,
|
Feb. 28,
|
Feb. 29,
|
|
|
2017
|
2016
|
2017
|
2016
|
|
Net
sales
|
100.0
%
|
100.0
%
|
100.0
%
|
100.0
%
|
|
Cost
of sales
|
81.2
|
89.9
|
65.8
|
59.5
|
|
Gross
profit
|
18.8
|
10.1
|
34.2
|
40.5
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
Selling,
general and administrative
|
64.3
|
101.1
|
42.1
|
40.6
|
|
Research
and development
|
46.6
|
77.1
|
27.5
|
25.3
|
|
Total
operating expenses
|
110.9
|
178.2
|
69.6
|
65.9
|
|
|
|
|
|
|
|
Loss
from operations
|
(92.1
)
|
(168.1
)
|
(35.4
)
|
(25.4
)
|
|
|
|
|
|
|
|
Interest
expense
|
(6.6
)
|
(9.8
)
|
(4.4
)
|
(3.4
)
|
|
Other
(expense) income, net
|
(0.1
)
|
(1.5
)
|
0.3
|
--
|
|
|
|
|
|
|
|
Loss before income tax
(expense) benefit
|
(98.8
)
|
(179.4
)
|
(39.5
)
|
(28.8
)
|
|
|
|
|
|
|
|
Income
tax (expense) benefit
|
(0.1
)
|
2.0
|
(0.3
)
|
--
|
|
Net
loss
|
(98.9
)
|
(177.4
)
|
(39.8
)
|
(28.8
)
|
|
Less:
Net income attributable to
the
noncontrolling interest
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
Net
loss attributable to Aehr Test Systems common
shareholders
|
(98.9
)%
|
(177.4
)%
|
(39.8
)%
|
(28.8
)%
|
|
|
Aehr Test
Systems
(Registrant)
|
|
|
|
|
|
|
|
|
Date: April 6,
2017
|
By:
|
/s/
GAYN
ERICKSON
|
|
|
|
|
Gayn
Erickson
|
|
|
|
|
President and Chief
Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: April 6,
2017
|
By:
|
/s/
KENNETH
B. SPINK
|
|
|
|
|
Kenneth B.
Spink
|
|
|
|
|
Vice President of
Finance and
Chief Financial
Officer
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
31.1
|
|
Certification of
Chief Executive Officer pursuant to Rules 13a-14(a) and
15d-14(a) promulgated under the Securities Exchange Act of 1934, as
amended, as adopted pursuant to Section 302(a) of the
Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
31.2
|
|
Certification of
Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a)
promulgated under the Securities Exchange Act of 1934, as amended,
as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of
2002.
|
|
|
|
|
|
32.1
|
|
Certification of
Chief Executive Officer and Chief Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.*
|
|
|
|
|
|
101.INS
|
|
XBRL Instance
Document
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy
Extension Schema Document
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy
Extension Calculation Linkbase Document
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy
Extension Definition Linkbase Document
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy
Extension Label Linkbase Document
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy
Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|